Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives "Sell (E+)" Rating from Weiss Ratings

Key Points

• Zentalis Pharmaceuticals received a "sell (E+)" rating from Weiss Ratings, while other analysts have issued mixed ratings, with one strong buy and one buy.
• The company's stock is currently trading at $1.72, with a consensus price target of $5.84 and a market capitalization of $123.72 million.
• In its latest earnings report, Zentalis posted a loss of ($0.37) per share, surpassing the consensus estimate of ($0.56) by $0.19.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report)'s stock had its "sell (e+)" rating restated by equities researchers at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

ZNTL has been the subject of several other research reports. HC Wainwright raised shares of Zentalis Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 7th. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Wells Fargo & Company cut their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $5.84.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL traded up $0.08 during mid-day trading on Friday, hitting $1.72. The company had a trading volume of 440,571 shares, compared to its average volume of 1,119,273. The firm has a fifty day moving average price of $1.62 and a 200 day moving average price of $1.43. Zentalis Pharmaceuticals has a one year low of $1.01 and a one year high of $4.44. The company has a market capitalization of $123.72 million, a PE ratio of -0.76 and a beta of 1.77.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.19. Research analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Catalyst Funds Management Pty Ltd purchased a new stake in Zentalis Pharmaceuticals during the second quarter valued at about $31,000. Cerity Partners LLC lifted its holdings in Zentalis Pharmaceuticals by 58.7% during the first quarter. Cerity Partners LLC now owns 20,501 shares of the company's stock valued at $33,000 after purchasing an additional 7,579 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in Zentalis Pharmaceuticals during the second quarter valued at about $37,000. Y Intercept Hong Kong Ltd purchased a new stake in Zentalis Pharmaceuticals during the second quarter valued at about $38,000. Finally, Corient Private Wealth LLC bought a new stake in shares of Zentalis Pharmaceuticals during the second quarter valued at about $41,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.